RapidAI, a global leader in AI and technology workflow solutions for neurovascular, cardiac, and vascular diseases, has successfully raised $75 million in its Series C funding round.
The funding was led by Vista Credit Partners, a subsidiary of Vista Equity Partners renowned for its expertise in enterprise software, data, and technology markets. The capital infusion will help fuel RapidAI’s pioneering platform innovation and expand its impact on life-threatening diseases across the globe.
At the forefront of clinical AI solutions, RapidAI’s advanced decision support software sets new benchmarks in patient care. Beyond traditional triage and notification capabilities, this state-of-the-art technology empowers physicians with highly accurate and context-rich data.
By providing specific and relevant information, RapidAI enables care teams to make faster, more informed decisions, ultimately improving patient outcomes.
Hospitals Embrace RapidAI Solutions
With an increasing number of hospitals worldwide adopting RapidAI’s solutions to address their critical needs, the company’s impact on clinical decision-making is becoming more pronounced.
RapidAI’s software is revolutionizing patient care in a myriad of life-threatening disease scenarios by streamlining care team workflows and supporting efficient decision-making.
One of RapidAI’s groundbreaking offerings is Rapid NCCT Stroke, the first and only FDA-cleared medical device to identify suspected intracranial hemorrhage and large vessel occlusion from non-contrast CT imaging.
With this technology, hospitals of all sizes gain greater access to imaging and decision support, significantly enhancing the management of stroke patients.
Expanding into New Disease States
Beyond stroke care, RapidAI’s innovative approach extends to other life-threatening conditions. The company’s FDA-cleared modules for cerebral aneurysm management and the detection and notification of suspected central pulmonary embolism exemplify their commitment to addressing diverse medical challenges.
With ongoing developments in additional modules for various disease states, RapidAI continues to pave the way for comprehensive clinical AI solutions.
The strategic partnership with Vista Credit Partners will be pivotal in RapidAI’s growth trajectory. With the support and expertise of Vista Credit Partners, RapidAI can advance its vision, technological innovations, and go-to-market efforts, further cementing its position as a global leader in clinical AI solutions for life-threatening diseases.
The far-reaching applications of AI span biomedical research, cancer screening, product development, treatment recommendation modeling, and administrative optimization, promising a brighter future for patient care and healthcare professionals.
The recent debut of AWS HealthScribe by Amazon Web Services (AWS) is another testament to AI’s growing influence in healthcare.
Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.
We Recommend:
- Connexpay secures $110 million funding to fuel global expansion
- Google Cloud invests $100 million in telehealth platform Amwell
- Drone startup Exyn Technologies bags $35 million from Reliance
- Software and payment company SpotOn nets $300 million for technology development
- Chowis’ AI Skin Diagnosis Solution “mySkin F.A.I.N” receives CES 2023 Innovation Award
